v3.26.1
Cover
Mar. 20, 2026
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 to the Current Report on Form 8-K (this “Amendment”), originally filed by Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on March 25, 2026 (the “Original Report”), is being filed to clarify that the actions previously reported as having been taken by the majority stockholders of the Company, as described in the Original Report, are null and void and of no force or effect.
Document Period End Date Mar. 20, 2026
Current Fiscal Year End Date --12-31
Entity File Number 001-42545
Entity Registrant Name Apimeds Pharmaceuticals US, Inc.
Entity Central Index Key 0001894525
Entity Tax Identification Number 85-1099700
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Matawan Rd
Entity Address, Address Line Two Suite 325
Entity Address, City or Town Matawan
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07747
City Area Code 848
Local Phone Number 201-5010
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol APUS
Security Exchange Name NYSEAMER
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false